Jpmorgan Chase & CO Seres Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,304 shares of MCRB stock, worth $1,069. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,304
Previous 39,443
96.69%
Holding current value
$1,069
Previous $30,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding MCRB
# of Institutions
93Shares Held
46.7MCall Options Held
119KPut Options Held
466K-
Flagship Pioneering Inc. Cambridge, MA23.1MShares$19 Million1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.29MShares$5.15 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.41MShares$1.97 Million0.21% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.78MShares$1.46 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.76MShares$1.44 Million0.0% of portfolio
About Seres Therapeutics, Inc.
- Ticker MCRB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,072,000
- Market Cap $102M
- Description
- Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...